GeneDx Holdings (WGS) Total Non-Current Liabilities (2020 - 2026)
GeneDx Holdings has reported Total Non-Current Liabilities over the past 7 years, most recently at $252.1 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 38.21% to $252.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $252.1 million through Mar 2026, up 38.21% year-over-year, with the annual reading at $213.9 million for FY2025, 26.85% up from the prior year.
- Total Non-Current Liabilities was $252.1 million for Q1 2026 at GeneDx Holdings, up from $213.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $288.7 million in Q2 2022 and troughed at $140.4 million in Q3 2023.
- The 5-year median for Total Non-Current Liabilities is $184.8 million (2022), against an average of $198.7 million.
- The largest YoY upside for Total Non-Current Liabilities was 74.37% in 2022 against a maximum downside of 54.55% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $213.2 million in 2022, then decreased by 17.45% to $176.0 million in 2023, then decreased by 4.2% to $168.6 million in 2024, then rose by 26.85% to $213.9 million in 2025, then increased by 17.87% to $252.1 million in 2026.
- Per Business Quant, the three most recent readings for WGS's Total Non-Current Liabilities are $252.1 million (Q1 2026), $213.9 million (Q4 2025), and $197.4 million (Q3 2025).